Too Little, Too Late? Heart Failure with Reduced Ejection Fraction (HFrEF)
A CardioAdvocate Phenotype
Published February 12, 2026 | Heart Failure Awareness Week
Case Presentation
Robert is a 58-year-old man with a history of hypertension, type 2 diabetes, obesity (BMI 34), and dyslipidemia. He has been on a low-dose ACE inhibitor and metformin for years but has never seen a cardiologist. His primary care physician noted a mildly elevated BNP on routine labs six months ago but attributed it to his weight and kidney function. No echocardiogram was ordered.
Robert presents to the emergency department with progressive shortness of breath over the past three weeks, now unable to walk from his car to the office without stopping. He has gained 12 pounds. His legs are swollen. He is sleeping propped up on three pillows. An echocardiogram reveals an ejection fraction of 25%. He is admitted with a diagnosis of new-onset heart failure with reduced ejection fraction (HFrEF).
But this is not new-onset disease. This is the culmination of years of cardiometabolic disease — hypertension, diabetes, obesity, dyslipidemia — left incompletely treated, inadequately monitored, and allowed to silently damage the heart muscle until it could no longer compensate.
Robert's hospitalization will cost approximately $14,000–$16,000. He has a 17% chance of being readmitted within 30 days. His 5-year survival, without aggressive treatment, is comparable to many cancers. And yet, with modern guideline-directed medical therapy (GDMT), much of this was preventable — and even now, much of the damage may be reversible.
Flying Under the Radar
Heart failure is often framed as an acute event — something that happens suddenly and requires hospitalization. In reality, it is almost always the end result of a spectrum of disease that progresses through recognizable stages, each offering an opportunity for intervention. The Universal Definition and Classification of Heart Failure describes four stages:
| Stage | Description | The Opportunity |
|---|---|---|
| A — At Risk | Hypertension, diabetes, obesity, CAD, metabolic syndrome, cardiotoxin exposure, genetic predisposition | Aggressive risk factor management can PREVENT structural heart disease from ever developing |
| B — Pre-Heart Failure | Structural heart disease or elevated biomarkers (BNP/NT-proBNP) but NO symptoms | Identification and treatment at this stage can PREVENT progression to symptomatic heart failure |
| C — Heart Failure | Current or prior symptoms of heart failure caused by structural/functional cardiac abnormality | GDMT can reverse damage, improve EF, reduce hospitalizations, and extend life |
| D — Advanced HF | Severe symptoms at rest; refractory to GDMT; recurrent hospitalizations | Advanced therapies (transplant, LVAD); this stage is often the consequence of inadequate Stage C treatment |
The tragedy of heart failure is not that we lack effective treatments — we have more effective therapies than at any point in the history of medicine. The tragedy is that we fail to use them. A landmark study published in JAMA Cardiology on January 28, 2026 reported that among 20,651 patients hospitalized with HFrEF who were eligible for all four pillars of GDMT, only 7.2% were prescribed all four medications. And among those on quadruple therapy, only 0.8% were at target doses for all drug classes.
Let that number settle: less than 1% of eligible patients are on the full, optimized therapy that has been proven to save lives. This is not a knowledge gap. The evidence is overwhelming. This is an implementation failure of staggering proportions.
Why Does Heart Failure Fly Under the Radar?
1. Cardiometabolic disease is treated in silos. Hypertension is managed by one provider, diabetes by another, cholesterol by a third. No one is looking at the cumulative burden these conditions place on the myocardium. An elevated BNP is dismissed as "not that high" or attributed to obesity or kidney disease. An echocardiogram is never ordered.
2. Stage B (pre-heart failure) is rarely identified. Patients with structural heart disease and no symptoms are not screened, not monitored, and not started on therapies that could prevent progression. The 2022 AHA/ACC/HFSA guidelines recommend screening with BNP/NT-proBNP and echocardiography in at-risk patients, yet this is inconsistently implemented.
3. Symptoms are attributed to deconditioning, aging, or obesity. "I'm just getting older." "I'm out of shape." "It's my weight." These explanations delay diagnosis by months or years.
4. Even when diagnosed, treatment is inadequate. GDMT is started too slowly, not titrated to goal, not all pillars are employed, and medications are stopped for side effects that are often preventable or manageable. Follow-up is too infrequent — the 2022 guidelines recommend every 1–3 weeks during titration, yet many patients are seen only every 3–6 months.
5. The "worse than cancer" label can become a self-fulfilling prophecy. Since the early 2000s, heart failure has been compared to cancer in terms of 5-year mortality — and at the population level, the comparison held. But unlike pancreatic cancer, where the diagnosis itself is often a death sentence, HFrEF is highly heterogeneous. There are multiple points along its course where prompt, appropriate intervention can halt progression, prevent hospitalization, and even promote recovery. When clinicians — particularly in hospice and palliative care settings — use the cancer analogy to frame a patient's prognosis, it can foster a sense of doom that discourages aggressive treatment. It can make patients feel hopeless, and it can lead clinicians to throw in the towel prematurely. HFrEF deserves to be understood on its own terms — and on those terms, modern GDMT makes it a fundamentally different disease.
The Four Pillars of GDMT
Modern heart failure therapy rests on four classes of medication, each independently shown to reduce mortality and hospitalizations in HFrEF. These are not optional add-ons — they are foundational, and every eligible patient should be on all four unless a genuine contraindication exists:
| Pillar | Drug Class | Key Benefit | Target |
|---|---|---|---|
| 1 | Beta-Blocker (carvedilol, metoprolol succinate, bisoprolol) | Reduces heart rate, reverses remodeling, reduces sudden death | Maximum tolerated dose |
| 2 | ARNI (sacubitril/valsartan) or ACEi/ARB | Neurohormonal blockade, reverse remodeling, mortality reduction; ARNI superior to ACEi (PARADIGM-HF) | Sacubitril/valsartan 97/103 mg BID |
| 3 | MRA (spironolactone or eplerenone) | Aldosterone blockade, reduces fibrosis; 30% mortality reduction (RALES) | Spironolactone 25–50 mg daily |
| 4 | SGLT2 Inhibitor (dapagliflozin or empagliflozin) | Reduces HF hospitalization and CV death; DAPA-HF and EMPEROR-Reduced; works regardless of diabetes status | Dapagliflozin 10 mg or empagliflozin 10 mg daily |
The combined effect of all four pillars is remarkable. Studies estimate that quadruple GDMT reduces the combined risk of cardiovascular death and heart failure hospitalization by approximately 60–70% compared to no therapy. When initiated rapidly and titrated to target doses, patients with new-onset HFrEF can see EF improvement in up to 77% of cases within one year, with a mean EF increase of over 20 points in patients who recover.
CardioAdvocate Checklist
Questions for Patients to Ask
Clinician Assessment Items
Deep Dive
Why GDMT Is Underused — And Why It Shouldn't Be
Polypharmacy Concerns
Clinicians and patients alike worry about taking "too many medications." This is understandable — but in HFrEF, the four pillars are not independent drugs treating separate problems. They are complementary therapies targeting different mechanisms of a single disease. Each pillar blocks a different pathway that drives heart failure progression: sympathetic activation, the renin-angiotensin-aldosterone system, aldosterone-mediated fibrosis, and sodium-glucose cotransporter-mediated volume and metabolic effects. Removing any one pillar leaves a pathway unblocked and the patient at increased risk.
Patients on optimized quadruple GDMT with an ARNI have been shown to have better survival than patients with many common cancers. The polypharmacy that treats heart failure is not the harmful polypharmacy of unnecessary medications — it is the deliberate, evidence-based deployment of life-saving therapies.
Cost and Prior Authorization Barriers
Generic sacubitril/valsartan is now available, substantially reducing the cost barrier for ARNI therapy. SGLT2 inhibitors are increasingly covered by insurance plans, with manufacturer copay assistance programs available for many patients.
The cost of NOT treating is staggering. A single heart failure hospitalization costs approximately $14,000–$16,000. The annual direct cost of heart failure hospitalizations in the United States exceeds $18.5 billion. The medications are not expensive relative to what they prevent.
Prior authorizations, while frustrating and time-consuming, should not be a reason to withhold life-saving therapy. The labor involved in a prior authorization is trivial compared to the labor (and cost) of managing a preventable heart failure hospitalization.
Preventable Side Effects
Hypotension: Heart failure medications lower blood pressure — that is part of how they work. A systolic blood pressure of 90–100 mmHg in an asymptomatic heart failure patient is often acceptable. Removing concomitant medications that are no longer needed can create room for GDMT. Equally important, furosemide and other loop diuretics can often be reduced or even eliminated as volume status stabilizes and GDMT begins to favorably alter hemodynamics.
Hyperkalemia: MRAs can raise potassium levels. This is manageable — monitor potassium regularly, adjust dietary intake, and consider potassium binders (patiromer, sodium zirconium cyclosilicate) if needed. The mortality benefit of MRAs far outweighs the manageable risk.
Bradycardia: Beta-blockers slow the heart rate. A heart rate in the 50s in an asymptomatic patient is generally well-tolerated and associated with improved outcomes.
Renal function changes: SGLT2 inhibitors and ARNI may cause an initial rise in creatinine — a "hemodynamic dip." This is typically transient and does not indicate true kidney injury. SGLT2 inhibitors are actually renoprotective over time (DAPA-CKD). Worsening renal function is frequently driven by excessive diuresis with loop diuretics rather than by GDMT itself.
The Loop Diuretic Trap: Furosemide Is Not GDMT
One of the most consequential misunderstandings in heart failure management is the treatment of loop diuretics as if they were a cornerstone of therapy. Furosemide relieves symptoms and reduces congestion, but with the exception of MRAs, diuretics have uncertain effects on morbidity and mortality.
The ACC explicitly states that "once approaching or achieving euvolemia, it is critical to add and optimize therapies proven to reduce morbidity and mortality." The ADA consensus report notes that higher loop diuretic doses are associated with elevated risks for adverse outcomes.
Think of a rowboat with holes in the hull, taking on water. Furosemide is the bucket you use to bail — necessary in the moment, but it does nothing to fix the holes. GDMT patches the holes. You may still need to bail for a while, but less and less frequently, and eventually you may not need the bucket at all.
Inadequate Follow-Up
The 2022 AHA/ACC/HFSA guidelines recommend follow-up every 1–3 weeks during GDMT titration. In practice, many patients are seen only every 3–6 months. The STRONG-HF trial demonstrated that frequent, structured follow-up produces dramatically better outcomes. A meta-analysis published in Preventing Chronic Disease showed that outpatient follow-up visits reduce 30-day all-cause readmissions by 21%.
The Reversibility of HFrEF: It's Not Too Late
One of the most important — and most under-communicated — facts about HFrEF is that it is often reversible. With optimal GDMT:
- Approximately 1 in 4 patients with HFrEF experience recovery of systolic function (EF improves to > 40%)
- In new-onset HFrEF, 46% improve above an EF of 35% by 90 days, 68% by 180 days, and 77% by one year
- The mean EF increase in patients who recover is over 21 percentage points
These numbers underscore a critical point: every day of delay in starting and optimizing GDMT is a day of potentially reversible damage going untreated.
The 2022 guidelines now formally recognize HFimpEF (heart failure with improved ejection fraction) as a distinct category. Critically, these patients should continue all GDMT indefinitely — discontinuation frequently leads to relapse and deterioration.
The Cancer Analogy: Fair Comparison or Dangerous Myth?
In 2001, a landmark Scottish study by Stewart and colleagues in the European Journal of Heart Failure posed a provocative question: is heart failure "more malignant than cancer?" The data were striking. Among patients admitted for the first time with heart failure, 5-year survival was worse than for bowel cancer in men and breast cancer in women — with only lung cancer carrying a grimmer prognosis. The comparison stuck. It was repeated in editorials, guidelines, palliative care literature, and medical education for two decades.
A 2017 Scottish primary care cohort study by Mamas et al. reinforced the message with 10-year follow-up: among 56,658 subjects, 5-year survival for heart failure was 55.8% in men (worse than prostate cancer at 68.3%) and 49.5% in women (far worse than breast cancer at 77.7%). The "worse than cancer" narrative became clinical gospel.
But this analogy, while statistically defensible at the population level, is misleading in ways that matter enormously for individual patients.
Why the Cancer Comparison Breaks Down
Consider the difference between HFrEF and pancreatic cancer. When pancreatic cancer is diagnosed — unless caught at its earliest stages — you can, tragically, almost put a stopwatch on it. The disease is usually metastatic at diagnosis, and 2-to-3 year survival is the exception, not the rule. The trajectory is relentlessly downward.
HFrEF is fundamentally different. It is highly heterogeneous — perhaps more so than any other cardiovascular condition. The prognosis depends not just on the diagnosis itself, but on the etiology (ischemic vs. non-ischemic), the degree of fibrosis and remodeling, the presence or absence of comorbidities, and — critically — whether the patient receives optimal therapy. A 50-year-old with new-onset non-ischemic cardiomyopathy who is rapidly started on all four pillars of GDMT has a completely different trajectory than a 78-year-old with ischemic cardiomyopathy, advanced fibrosis, and Stage D heart failure. Lumping them under the same "worse than cancer" umbrella does both patients a disservice.
Modern GDMT Has Changed the Equation
The most powerful rebuttal to the cancer analogy comes from the data itself. A 2025 analysis from the TriNetX Global Collaborative Research Network examined 32,125 patients with HFrEF on full GDMT, 403,389 patients with HFrEF not on full GDMT, and over 2.4 million patients with malignant cancers. The findings were striking: HFrEF patients on comprehensive GDMT (including ARNI) had significantly better survival than matched cancer patients (HR 0.44; 95% CI 0.41–0.47). Patients NOT on full GDMT fared worse than cancer. In other words, the cancer analogy is only true if we fail to treat heart failure properly — and it becomes false the moment we do.
A 2023 editorial in the Journal of the American Heart Association captured this beautifully, framing acute heart failure as a "malignant process" but one in which we can "induce remission" — patients remain alive and progression-free, without repeat hospitalization, for extended periods. Critically, the treatments that achieve this remission are not the toxic chemotherapy regimens of oncology. Heart failure medications — beta-blockers, ARNI, MRAs, SGLT2 inhibitors — carry side effects that are generally manageable and are fundamentally non-toxic. You don't lose your hair. You don't become immunosuppressed. The medications make you feel better, not worse.
The Hospitalization Mortality Trap — and the Way Out
It is true that each hospitalization for heart failure exacerbation carries significant prognostic implications — post-hospitalization mortality rates are sobering, with 1-year mortality ranging from 28% to 36% depending on the cohort. And it is true that, like cancer, stopping heart failure therapy can lead to relapse — the TRED-HF trial showed a 44% relapse rate within 6 months of GDMT withdrawal in patients with recovered EF. In that narrow sense, the cancer parallel holds: treatment must be maintained indefinitely.
But here is the crucial difference: at nearly every point along the heart failure continuum, there is an intervention that can change the trajectory. Stage A patients can prevent structural disease. Stage B patients can prevent symptoms. Stage C patients can reverse damage. Even Stage D patients have options — LVADs, transplant, advanced therapies. This is not the inexorable march of metastatic cancer. This is a disease with off-ramps, and we have the tools to take them.
The Danger of the Analogy in Clinical Practice
In clinical practice, the cancer analogy is most commonly invoked by hospice and palliative care clinicians — often with the best of intentions. They see the mortality statistics and use the comparison to help patients and families understand the seriousness of heart failure. But research on palliative care barriers in heart failure has documented the unintended consequences:
- Patient demoralization: Being told your disease is "worse than cancer" can induce hopelessness — particularly when the patient may have a highly treatable form of HFrEF with significant recovery potential.
- Premature treatment withdrawal: Clinicians who view heart failure through a cancer lens may be more inclined to scale back therapy rather than escalate it, especially in older patients or those who have been hospitalized multiple times.
- Inappropriate hospice timing: Studies show that the median time between hospice enrollment and death in heart failure is just 3 days — compared to much longer planned transitions in cancer — because the disease trajectory is unpredictable, with sudden decompensations followed by recoveries that cancer simply does not exhibit.
- Missed therapeutic windows: A patient labeled as "end-stage" who has never been on optimized GDMT is not truly end-stage — they are undertreated. The label closes doors that should remain open.
The American Heart Association has recognized that palliative care models designed for cancer cannot simply be transplanted onto heart failure. HF requires its own frameworks — ones that account for its heterogeneity, its treatability, its capacity for recovery, and the fundamentally non-toxic nature of its therapies.
Putting It Simply: The Heart–Kidney Battle
Here is how I explain this to my patients: Your heart and your kidneys are locked in an epic battle — and neither one knows it's making the other worse.
When your heart weakens, two things happen to your kidneys. First, they receive less blood flow because the heart can't pump as forcefully. Second — and this is just as important — blood backs up behind the weakened heart, creating venous congestion that swells the kidneys from the inside, like a traffic jam that makes it impossible for them to do their job. Research increasingly shows that this backward pressure on the kidneys may be even more damaging than the reduced forward flow (Mullens et al., European Heart Journal).
Your kidneys respond to both problems the same way: they think you're in the desert, dying of thirst. So they hold onto every drop of fluid and every grain of salt they can, and they signal your blood vessels to tighten up. This temporarily helps maintain blood flow — but it floods your already-struggling heart with even more volume and resistance.
Now the cycle accelerates. This is the cardiorenal syndrome — a vicious cycle that, left unchecked, spirals toward hospitalization (Rangaswami et al., Circulation).
This is exactly where GDMT steps in. Think of your weakened heart trying to bench press. The extra fluid is weight plates being stacked onto the bar by your own kidneys. Each pillar of GDMT removes plates from that bar: ARNIs reduce the fluid and relax the vessels, beta-blockers calm the racing nervous system, MRAs block the salt-retaining hormone aldosterone, and SGLT2 inhibitors offload fluid while protecting both the heart and the kidneys simultaneously.
We add these medications gradually — start one, let your body adjust over one to three weeks, then add the next or increase the dose. It's like removing one plate at a time so your heart can get stronger with each step. That's why rapid, systematic titration matters: every week at a suboptimal dose is another week the vicious cycle keeps spinning.
Pathophysiology: How the Heart Fails
The normal left ventricle ejects approximately 55–70% of its blood volume with each beat (the ejection fraction). In HFrEF, this drops to 40% or below. The causes of myocardial injury are numerous. Coronary artery disease remains the most common etiology, but the growing epidemic of cardiometabolic disease — the interplay of hypertension, diabetes, obesity, and dyslipidemia — drives a distinct form of non-ischemic myocardial dysfunction.
When the myocardium is injured, the body activates compensatory neurohormonal systems. The sympathetic nervous system increases heart rate and contractility. The renin-angiotensin-aldosterone system (RAAS) retains sodium and water. These mechanisms temporarily sustain cardiac output — but over time, they become maladaptive. Chronic sympathetic activation leads to myocyte apoptosis, arrhythmias, and further remodeling. Chronic RAAS activation leads to fibrosis, fluid overload, and progressive ventricular dilation. This is why the four pillars of GDMT are so effective: each one blocks a distinct arm of this maladaptive neurohormonal cascade.
Diagnosis: Finding Heart Failure Before It Finds You
Biomarkers
BNP and NT-proBNP are released by cardiomyocytes in response to myocardial stretch and volume overload. BNP > 35 pg/mL or NT-proBNP > 125 pg/mL in the outpatient setting warrants further investigation per the 2022 guidelines.
Echocardiography
Transthoracic echocardiography remains the cornerstone of HFrEF diagnosis and monitoring. See the CardioAdvocate Echo Guide for a patient-friendly overview. Serial echocardiography is essential — reassessment at 3–6 months after GDMT initiation evaluates for EF recovery and guides device therapy decisions.
Cardiac MRI
Cardiac MRI with late gadolinium enhancement provides the most accurate EF measurement and can identify the etiology of cardiomyopathy by characterizing the pattern and extent of myocardial scar, fibrosis, and edema.
The Treatment Landscape: From Four Pillars to Comprehensive Care
Beta-Blockers: Taming the Sympathetic Storm
Three beta-blockers have demonstrated mortality benefit in HFrEF: carvedilol, metoprolol succinate (the extended-release — not metoprolol tartrate), and bisoprolol. These three — and only these three — have robust mortality data. The target is maximum tolerated dose. Beta-blockers should generally not be initiated during acute decompensation.
ARNI: The Superior Neurohormonal Blockade
The PARADIGM-HF trial demonstrated a 20% relative risk reduction in cardiovascular death or heart failure hospitalization compared to enalapril. The PIONEER-HF trial demonstrated that de novo initiation in hospitalized patients is safe and effective. Generic formulations are now available. A mandatory 36-hour washout period when switching from an ACE inhibitor is required to prevent angioedema.
MRA: Blocking the Fibrosis Pathway
The RALES trial (1999) demonstrated a 30% reduction in all-cause mortality with spironolactone in severe HFrEF. The EMPHASIS-HF trial (2011) extended this benefit to mild-to-moderate HFrEF with eplerenone.
SGLT2 Inhibitors: The Newest Pillar
The DAPA-HF trial (2019) and EMPEROR-Reduced trial (2020) demonstrated approximately 25% reduction in the combined endpoint — regardless of diabetes status. A recent meta-analysis now supports initiating SGLT2 inhibitors during heart failure hospitalization rather than waiting until discharge.
Beyond the Four Pillars
Hydralazine/Isosorbide Dinitrate (H-ISDN): Recommended as add-on therapy for self-identified Black patients with persistent symptoms despite optimal GDMT. The A-HeFT trial demonstrated a 43% relative risk reduction in mortality.
Ivabradine: Selectively reduces heart rate without affecting blood pressure. Recommended for patients in sinus rhythm with resting heart rate ≥ 70 bpm despite maximally tolerated beta-blocker therapy.
Vericiguat: A soluble guanylate cyclase stimulator. The VICTORIA trial showed modest benefit. The more recent VICTOR trial showed a mortality signal that has generated interest in whether vericiguat may eventually become a fifth pillar for select patients.
Device Therapy (ICDs and CRT): ICDs are recommended for patients whose EF remains ≤ 35% after at least 3 months of optimized GDMT. CRT is indicated for patients with EF ≤ 35%, NYHA class II–IV, sinus rhythm, and QRS ≥ 150 ms with LBBB morphology.
The Hospitalization as a Golden Window: Inpatient GDMT Initiation
There is a dangerous misconception that heart failure medications should be started cautiously, one at a time, in the outpatient setting after the dust has settled. In fact, the hospitalization itself is the single greatest therapeutic opportunity we have — and squandering it is one of the most consequential failures in heart failure care.
Why? Because the patient is a captive audience. Vital signs are monitored continuously. Labs can be checked daily. Medications can be started under observation. And most importantly — the medications you are prescribed at discharge are the medications you are most likely to remain on long-term. Research on Part D claims after heart failure hospitalization shows that patients who fill their prescriptions within 30 days of discharge have dramatically better 12-month adherence: 60–63% for beta-blockers and ACE-I/ARBs, compared to far lower rates when initiation is deferred. The discharge prescription exerts an inertia — for better or worse, what goes home with you tends to stick.
The Evidence for Starting Early
Multiple landmark trials have now demonstrated that initiating GDMT pillars during hospitalization — once the patient is hemodynamically stable — is not only safe but produces measurably better outcomes:
- ARNI: The PIONEER-HF trial randomized 881 patients with acute decompensated HFrEF to sacubitril/valsartan versus enalapril during the hospitalization. ARNI produced greater NT-proBNP reduction with no increase in hypotension, hyperkalemia, or renal dysfunction. Heart failure rehospitalization at 8 weeks was lower in the ARNI group.
- SGLT2i: The EMPULSE trial randomized 530 patients to empagliflozin versus placebo a median of 3 days after admission. The win ratio favored empagliflozin (1.36; P=0.005), with lower mortality (4.2% vs. 8.3%) and fewer heart failure events (10.6% vs. 14.7%). The SOLOIST-WHF trial confirmed that dual SGLT1/SGLT2 inhibition with sotagliflozin, initiated before or shortly after discharge, significantly reduced cardiovascular death and heart failure events.
- Rapid multi-pillar titration: The STRONG-HF trial demonstrated that high-intensity, rapid titration of all GDMT pillars to 100% target doses within 2 weeks post-discharge — supported by clinic visits every 1–2 weeks — reduced death or heart failure readmission by 34% at 180 days. The trial was stopped early because the benefit was so overwhelming.
- Additive discharge benefit: A 2025 multi-institutional study in JACC: Advances showed that each additional GDMT class prescribed at discharge independently and progressively reduces 30-day readmission risk — patients discharged on all four pillars had a 44% lower readmission rate (HR 0.56) compared to those on just one.
Why Real-World Practice Falls Short
If the evidence is so clear, why aren't we doing it? The barriers are real — but they are surmountable:
- Short length of stay: The average heart failure hospitalization is 4–5 days. There simply isn't time to titrate every medication to target during the stay. But that's not the goal — the goal is to initiate all four pillars at low doses, then titrate rapidly in the outpatient setting as STRONG-HF demonstrated.
- Clinical inertia: Studies on prescribing behavior show that clinical inertia — the failure to intensify therapy when it is clearly indicated — accounts for 23–32% of missed optimization opportunities. Physicians hesitate, delay, or defer out of habit, not evidence.
- Prior authorization at discharge: ARNI and SGLT2 inhibitors often require prior authorization. When a patient is being discharged on a Friday afternoon and the PA hasn't been processed, the path of least resistance is to send them home on an ACE inhibitor instead — and the ARNI never gets started. Generic sacubitril/valsartan has eased this, but the friction remains.
- Fear of side effects: Hypotension, bradycardia, hyperkalemia, and transient creatinine rises are common during acute decompensation. But PIONEER-HF, EMPULSE, and STRONG-HF all demonstrated that initiating GDMT once the patient is stabilized carries no excess serious adverse events. The transient hemodynamic dip is expected and manageable — it is not a reason to withhold therapy.
- Inadequate outpatient follow-up infrastructure: STRONG-HF used visits every 1–2 weeks. The real world offers every 3–6 months. Without close post-discharge monitoring, clinicians are understandably cautious about sending patients home on four new medications. Building the infrastructure for frequent, protocol-driven follow-up is the critical missing link.
- Cost concerns: Even with generic ARNI available, out-of-pocket costs for SGLT2 inhibitors can reach $500–800/month without insurance coverage. Manufacturer copay programs help, but require additional effort to enroll. The irony: the cost of a single preventable rehospitalization ($14,000–$16,000) dwarfs the annual cost of GDMT.
The Implementation Gap We Must Close
The DAPA ACT HF-TIMI 68 trial, published in Circulation in 2025, randomized 2,401 patients to in-hospital dapagliflozin and, while the primary endpoint did not reach significance, the pooled meta-analysis across all SGLT2i trials confirms a consistent mortality signal with early initiation. The evidence is not ambiguous — it points overwhelmingly in one direction: start early, start all four, titrate fast, follow up closely.
The JAMA Cardiology data shows that hospitals with higher GDMT scores at discharge — meaning more patients leave on more of the four pillars — have lower mortality, lower readmissions, and lower costs. It is not just good medicine. It is cost-effective medicine.
What we need is not more data. We need systems that ensure every eligible patient hospitalized with HFrEF is discharged on all four pillars — at initiated doses — with a structured 1–2 week outpatient follow-up plan for rapid titration. This is a protocol problem, not a knowledge problem. The knowledge has been settled. The implementation has not.
What the Latest Data Tells Us
JAMA Cardiology, January 28, 2026: Among 20,651 HFrEF patients eligible for all four pillars, only 7.2% were prescribed all four medications, and only 0.8% were at target doses. Higher hospital GDMT scores at discharge were associated with lower mortality, lower rehospitalization, and lower costs.
ESC meta-analysis, February 2026: Supports initiation of SGLT2 inhibitors during heart failure hospitalization, showing significant reductions in early cardiovascular death or worsening heart failure.
Heart failure survival vs. cancer (JAHA): Patients with HFrEF on GDMT with ARNI had significantly better survival than patients with many common malignancies.
Controversies and Evolving Evidence
When to Stop GDMT After EF Recovery
The short answer: don't. The TRED-HF trial randomized patients with recovered HFrEF to phased GDMT withdrawal versus continued therapy. The withdrawal group had a 44% relapse rate within 6 months. A recovered EF does not mean a cured heart. It means the medications are working.
Iron Deficiency in Heart Failure
Iron deficiency is present in approximately 50% of heart failure patients. The FAIR-HF and AFFIRM-AHF trials demonstrated that IV ferric carboxymaltose improves functional status. The guidelines recommend screening all heart failure patients for iron deficiency (ferritin < 100 ng/mL, or ferritin 100–299 ng/mL with transferrin saturation < 20%).
The Economics of Heart Failure: Why GDMT Is a Bargain
According to AHA Heart Disease and Stroke Statistics 2025, total annual cost of heart failure in the United States exceeds $43 billion. Average cost per hospitalization is approximately $14,000–$16,000. Heart failure is the leading cause of hospitalization in patients over age 65. The JAMA Cardiology study (2026) demonstrated that hospitals with higher GDMT scores had lower mortality, lower readmissions, and lower total costs.
Future Directions
Cardiac myosin activators (omecamtiv mecarbil) — the GALACTIC-HF trial showed modest but significant reductions in heart failure events.
GLP-1 receptor agonists (semaglutide) — the STEP-HFpEF trial demonstrated significant benefits in HFpEF with obesity. Trials are ongoing in HFrEF.
Remote monitoring — the CHAMPION trial demonstrated that implantable hemodynamic monitors (CardioMEMS) reduce heart failure hospitalizations.
Gene therapy — early-phase trials are exploring gene-based approaches to restore sarcoplasmic reticulum calcium handling. See Rewriting the Code: Gene Editing in Medicine.
Landmark References
- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Heidenreich PA, Bozkurt B, et al. Circulation. 2022.
- PARADIGM-HF: Sacubitril/Valsartan vs. Enalapril. McMurray JJV, et al. NEJM. 2014.
- DAPA-HF: Dapagliflozin in HFrEF. McMurray JJV, et al. NEJM. 2019.
- EMPEROR-Reduced: Empagliflozin in HFrEF. Packer M, et al. NEJM. 2020.
- RALES: Spironolactone in Severe HFrEF. Pitt B, et al. NEJM. 1999.
- EMPHASIS-HF: Eplerenone in Mild HFrEF. Zannad F, et al. NEJM. 2011.
- STRONG-HF: Rapid GDMT Titration. Mebazaa A, et al. Lancet. 2022.
- Universal Definition and Classification of Heart Failure. Bozkurt B, et al. JACC. 2021.
- JAMA Cardiology 2026: GDMT Utilization in HFrEF. 7.2% on all four pillars, 0.8% at target doses.
- DAPA-CKD: Renoprotection with Dapagliflozin. Heerspink HJL, et al. NEJM. 2020.
- More 'Malignant' Than Cancer? Five-Year Survival Following a First Admission for Heart Failure. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. Eur J Heart Fail. 2001;3:315–322.
- Do Patients Have Worse Outcomes in Heart Failure Than in Cancer? A Primary Care-Based Cohort Study. Mamas MA, Sperrin M, et al. Eur J Heart Fail. 2017;19:1095–1104.
- Acute Heart Failure Is a Malignant Process — But We Can Induce Remission. JAHA. 2023.
- EMPULSE: In-Hospital Empagliflozin in Acute Heart Failure. Voors AA, et al. Nature Medicine. 2022.
- SOLOIST-WHF: Sotagliflozin in Diabetes and Recent Worsening Heart Failure. Bhatt DL, et al. NEJM. 2020.
- DAPA ACT HF-TIMI 68: In-Hospital Dapagliflozin in Heart Failure. Morrow DA, et al. Circulation. 2025.
- Additive Benefit of GDMT at Discharge in Reducing 30-Day Readmissions. JACC: Advances. 2025.
The Bottom Line
Heart failure with reduced ejection fraction is not a sudden event — it is the preventable culmination of cardiometabolic disease left unrecognized, untreated, or incompletely treated.
It is a spectrum of disease that can be interrupted at every stage. Hypertension, diabetes, obesity, and dyslipidemia are not just risk factors — they are the substrates of heart failure. An elevated BNP, a declining EF, new-onset exertional dyspnea — these are not incidental findings to monitor. They are calls to action.
When HFrEF is diagnosed, we have four pillars of therapy that can reduce death and hospitalization by 60–70%, reverse cardiac damage in up to 77% of patients within a year, and deliver survival that exceeds many common cancers. Yet only 7.2% of eligible patients receive all four medications, and less than 1% are at target doses.
Heart failure is not a disease of too many medications. It is a disease of too few, given too late, titrated too slowly, stopped too soon, and followed up too infrequently. We can do better. We must do better.
CardioAdvocate helps people understand what matters — and how to speak up about it.
